keyword
MENU ▼
Read by QxMD icon Read
search

Eye anti-VEGF

keyword
https://www.readbyqxmd.com/read/28088487/adenosine-receptors-and-caffeine-in-retinopathy-of-prematurity
#1
REVIEW
Jiang-Fan Chen, Shuya Zhang, Rong Zhou, Zhenlang Lin, Xiaohong Cai, Jing Lin, Yuqin Huo, Xiaoling Liu
Retinopathy of prematurity (ROP) is a major cause of childhood blindness in the world and is caused by oxygen-induced damage to the developing retinal vasculature, resulting in hyperoxia-induced vaso-obliteration and subsequent delayed retinal vascularization and hypoxia-induced pathological neovascularization driven by vascular endothelial growth factor (VEGF) signaling pathway in retina. Current anti-VEGF therapy has shown some effective in a clinical trial, but is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants...
January 11, 2017: Molecular Aspects of Medicine
https://www.readbyqxmd.com/read/28077879/determinants-of-visual-acuity-outcomes-in-eyes-with-neovascular-amd-treated-with-anti-vegf-agents-an-instrumental-variable-analysis-of-the-aura-study
#2
F G Holz, R Tadayoni, S Beatty, A R Berger, M G Cereda, P Hykin, G Staurenghi, K Wittrup-Jensen, J Nilsson, K Kim, S Sivaprasad
No abstract text is available yet for this article.
January 2017: Eye
https://www.readbyqxmd.com/read/28053502/neovascular-age-related-macular-degeneration-without-drusen-in-the-fellow-eye-clinical-spectrum-and-therapeutic-outcome
#3
Wing H Chung, Elon H C van Dijk, Danial Mohabati, Greet Dijkman, Suzanne Yzer, Eiko K de Jong, Sascha Fauser, Reinier O Schlingemann, Carel B Hoyng, Camiel J F Boon
PURPOSE: To investigate the clinical characteristics and therapeutic outcome of patients with neovascular age-related macular degeneration (nAMD) in 1 eye, without drusen in the fellow eye. PATIENTS AND METHODS: Medical records of 381 patients were analyzed to identify the cases. The main outcomes included Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and change in central retinal thickness (CRT). These parameters were reviewed at baseline, first follow-up visit, and after 6, 12, and 24 months...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28048946/intravitreal-anti-vascular-endothelial-growth-factor-drugs-for-retinal-angiomatous-proliferation-in-real-life-practice
#4
Maurizio Battaglia Parodi, Simone Donati, Francesco Semeraro, Paola Danzi, Ugo Introini, Francesco Viola, Ferdinando Bottoni, Vincenzo Pucci, Andrea Musig, Alfredo Pece, Claudio Azzolini
PURPOSE: To describe the outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in the treatment of retinal angiomatous proliferation (RAP) in real-life practice in 7 Italian centers under the Progetto Luce initiative. METHODS: Clinical data of 95 eyes of 95 patients affected by RAP, regularly followed up and treated with either intravitreal ranibizumab or bevacizumab over 12 months, were examined. After a loading phase of 3 consecutive injections, retreatments were administered following a pro-re-nata regimen on the basis of the persistence or the recurrence of subretinal/intraretinal fluid on optical coherence tomography, or leakage on fluorescein angiography...
January 3, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#5
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28028001/pharmacokinetic-aspects-of-retinal-drug-delivery
#6
REVIEW
Eva M Del Amo, Anna-Kaisa Rimpelä, Emma Heikkinen, Otto K Kari, Eva Ramsay, Tatu Lajunen, Mechthild Schmitt, Laura Pelkonen, Madhushree Bhattacharya, Dominique Richardson, Astrid Subrizi, Tiina Turunen, Mika Reinisalo, Jaakko Itkonen, Elisa Toropainen, Marco Casteleijn, Heidi Kidron, Maxim Antopolsky, Kati-Sisko Vellonen, Marika Ruponen, Arto Urtti
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical...
December 24, 2016: Progress in Retinal and Eye Research
https://www.readbyqxmd.com/read/28003779/pneumatic-displacement-of-submacular-haemorrhage
#7
Ehab Abdelkader, Kay P Yip, Kurt Spiteri Cornish
PURPOSE: To evaluate the outcomes of pneumatic displacement of submacular hemorrhage secondary to choroidal neovascular membrane (CNV) (n = 9) and retinal arterial macroaneurysm (RAM) (n = 3). METHODS: This is a retrospective case series study of 12 eyes from 12 patients in Aberdeen Royal Infirmary, Aberdeen, UK. The mean duration of visual loss was 10.8 ± 4.11 days. All cases received intravitreal injection of expansile gas within 24 h of presentation (C3F8 in 11 cases and SF6 in one case) and postured face down for five days...
October 2016: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28002284/outcomes-of-anti-vegf-therapy-in-choroidal-neovascularization-after-macular-surgery
#8
Duc Anh Hua, Antonio M Casella, Maria H Berrocal, Dennis Han, Rayan A Alshareef, Hugo Quiroz-Mercado, J Fernando Arevalo, Jay Chhablani
PURPOSE: To report treatment outcomes of anti-vascular endothelial growth factor (VEGF) therapy in choroidal neovascularization (CNV) presenting after macular surgery. METHODS: Retrospective analysis of 7 eyes of 7 patients, who were diagnosed to have CNV after macular surgery and were treated with anti-vascular endothelial growth factor therapy. Collected data included demographic details; history of present illness; surgical procedure; and clinical examination including visual acuity at presentation and follow-up with imaging and management...
December 20, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27994435/pkr-promotes-choroidal-neovascularization-via-upregulating-the-pi3k-akt-signaling-pathway-in-vegf-expression
#9
Manhui Zhu, Xiaojuan Liu, Shengcun Wang, Jin Miao, Liucheng Wu, Xiaowei Yang, Ying Wang, Lihua Kang, Wendie Li, Chen Cui, Hui Chen, Aimin Sang
PURPOSE: The aim of this study was to investigate the functions of dsRNA-activated protein kinase (PKR) in choroidal neovascularization (CNV) and related signaling pathways in the production of vascular endothelial growth factor (VEGF). METHODS: A chemical hypoxia model of in vitro RF/6A cells, a rhesus choroid-retinal endothelial cell line, was established by adding cobalt chloride (CoCl2) to the culture medium. PKR, phosphophosphatidylinositol 3-kinase (p-PI3K), phosphoprotein kinase B (p-Akt), and VEGF protein levels in RF/6A cells were detected with western blotting...
2016: Molecular Vision
https://www.readbyqxmd.com/read/27993591/histopathologic-characterization-of-the-expression-of-vascular-endothelial-growth-factor-in-a-case-of-retinopathy-of-prematurity-treated-with-ranibizumab
#10
Maria P Fernandez, Audina M Berrocal, Tyler C Goff, Mark P Ghassibi, Clio A Harper, Eva Chou, Simon K Michael, Justin Hellman, Sander R Dubovy
PURPOSE: To characterize the expression of Vascular Endothelial Growth Factor (VEGF) in a patient with Retinopathy of prematurity (ROP) treated with Ranibizumab (Case 1) and compare it to a case of ROP without treatment (Case 2), a case of a premature baby without ROP (Case 3) and a case of a baby without history of ROP or prematurity (Case 4). DESIGN: Observational case series METHODS: The eyes of the deceased babies were removed post mortem and were sent to the Florida Lions Ocular Pathology Laboratory where they were processed...
December 16, 2016: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27991837/vision-preservation-in-eyes-of-polypoidal-choroidal-vasculopathy-with-low-dose-intravitreal-triamcinolone-acetonide
#11
I-Chia Liang, Yi-Ru Lin, Hsiang-Wen Chien, Kwan-Rong Liu
PURPOSE: To evaluate the efficacy and adverse effects of using low-dose intravitreal triamcinolone acetonide (IVTA) to preserve vision in polypoidal choroidal vasculopathy (PCV) eyes. METHODS: This retrospective chart review study examined 8 eyes of 7 PCV patients, for whom verteporfin photodynamic therapy (vPDT) or antivascular endothelial growth factor (VEGF) therapy was not affordable/available and also with intolerable risk because of underlying cardiovascular and/or cerebrovascular ischemia...
January 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27990354/effect-of-trapping-vascular-endothelial-growth-factor-a-in-a-murine-model-of-dry-eye-with-inflammatory-neovascularization
#12
Jin Woo Kwon, Jin A Choi, Eun Young Shin, Tae Yoon La, Dong Hyun Jee, Yeon Woong Chung, Yang Kyung Cho
AIM: To evaluate whether trapping vascular endothelial growth factor A (VEGF-A) would suppress angiogenesis and inflammation in dry eye corneas in a murine corneal suture model. METHODS: We established two groups of animals, one with non-dry eyes and the other with induced dry eyes. In both groups, a corneal suture model was used to induce inflammation and neovascularization. Each of two groups was again divided into three subgroups according to the treatment; subgroup I (aflibercept), subgroup II (dexamethasone) and subgroup III (phosphate buffered saline, PBS)...
2016: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/27977064/anti-vascular-endothelial-growth-factor-for-choroidal-neovascularisation-in-people-with-pathological-myopia
#13
REVIEW
Ying Zhu, Ting Zhang, Gezhi Xu, Lijun Peng
BACKGROUND: Choroidal neovascularisation (CNV) is a common complication of pathological myopia. Once developed, most eyes with myopic CNV (mCNV) experience a progression to macular atrophy, which leads to irreversible vision loss. Anti-vascular endothelial growth factor (anti-VEGF) therapy is used to treat diseases characterised by neovascularisation and is increasingly used to treat mCNV. OBJECTIVES: To assess the effects of anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation (CNV), compared with other treatments, sham treatment or no treatment, in people with pathological myopia...
15, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27967247/how-are-we-improving-the-delivery-to-back-of-the-eye-advances-and-challenges-of-novel-therapeutic-approaches
#14
Vibhuti Agrahari, Vivek Agrahari, Abhirup Mandal, Dhananjay Pal, Ashim K Mitra
Drug delivery to the back of the eye requires strategic approaches that guarantee the long-term therapeutic effect with patient compliance. Current treatments for posterior eye diseases suffer from significant challenges including frequent intraocular injections of anti-VEGF agents and related adverse effects in addition to the high cost of the therapy. Areas covered: Treatment challenges and promising drug delivery approaches for posterior segment eye diseases, such as age-related macular degeneration (AMD) are summarized...
December 28, 2016: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/27957600/vitreoretinal-interface-abnormalities-in-patients-treatedwith-ranibizumab-for-diabetic-macular-oedema
#15
Yun Wong, David H W Steel, Maged S Habib, Alex Stubbing-Moore, Dalvir Bajwa, Peter J Avery
PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) agents are effective in the treatment of central involving diabetic macular oedema (DMO). Vitreoretinal interface abnormalities (VRIA) are common in patients with DMO, and the effect of these on the response to anti-VEGF treatment is unclear. Furthermore the effect of anti-VEGF agents on the VRIA itself is uncertain. METHOD: Prospective study of consecutive patients treated with ranibizumab (RZB) for DMO as part of routine clinical care in one eye unit over a 1-year period...
December 12, 2016: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27928444/the-remote-effects-of-intravitreal-anti-vegf-therapy
#16
Balta F, Merticariu M, Taban C, Neculau G, Merticariu A, Muresanu D, Badescu D, Jinga V
Objective: To study the effects of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) therapy with Avastin for wet Age-Related Macular Degeneration (AMD) on Benign Prostatic Hyperplasia (BPH)-related symptoms. Methods: An exploratory trial was conducted from August 1, 2013 to February 1, 2014, that included 14 male patients previously diagnosed with BPH, who were aged between 59 and 69 years. The trial was performed in Bucharest and involved two medical institutions: the Clinical Hospital of Eye Emergencies and the "Prof...
October 2016: Journal of Medicine and Life
https://www.readbyqxmd.com/read/27918469/dietary-compound-chrysin-inhibits-retinal-neovascularization-with-abnormal-capillaries-in-db-db-mice
#17
Min-Kyung Kang, Sin-Hye Park, Yun-Ho Kim, Eun-Jung Lee, Lucia Dwi Antika, Dong Yeon Kim, Yean-Jung Choi, Young-Hee Kang
Diabetic retinopathy (DR) develops in a significant proportion of patients with chronic diabetes, characterized by retinal macular edema and abnormal retinal vessel outgrowth leading to vision loss. Chrysin, a naturally-occurring flavonoid found in herb and honeycomb, has anti-inflammatory, antioxidant, and anti-cancer properties. This study sought to determine the protective effects of chrysin on retinal neovascularization with abnormal vessels and blood-retinal barrier (BRB) breakdown in 33 mM glucose-exposed human retinal endothelial cells and in db/db mouse eyes...
December 3, 2016: Nutrients
https://www.readbyqxmd.com/read/27915321/anti-vascular-endothelial-growth-factor-preparations-in-the-treatment-of-retinopathy-of-prematurity-balancing-risks-and-benefits
#18
Deepak Chawla, Brian A Darlow
NEED AND PURPOSE OF REVIEW: The standard of management of severe retinopathy of prematurity (ROP) is laser ablation of the peripheral retina. Intra-vitreal injection of anti- vascular endothelial growth factor antibodies has emerged as an alternative modality of treatment of ROP. The purpose of this review is to evaluate the current evidence on benefits and risks of using anti-VEGF antibodies for management of ROP. METHODS: PubMed and Cochrane Register of Clinical Trials were searched for studies evaluating role of anti-VEGF agents in ROP...
November 7, 2016: Indian Pediatrics
https://www.readbyqxmd.com/read/27913654/novel-small-molecule-jp-153-targets-the-src-fak-paxillin-signaling-complex-to-inhibit-vegf-induced-retinal-angiogenesis
#19
Jordan J Toutounchian, Jayaprakash Pagadala, Duane D Miller, Jerome Baudry, Frank Park, Edward Chaum, Charles R Yates
Targeting vascular endothelial growth factor (VEGF) is a common treatment strategy for neovascular eye disease, a major cause of vision loss in diabetic retinopathy and age-related macular degeneration. However, the decline in clinical efficacy over time in many patients suggests that monotherapy of anti-VEGF protein therapeutics may benefit from adjunctive treatments. Our previous work has shown that through decreased activation of the cytoskeletal protein paxillin, growth factor-induced ischemic retinopathy in the murine oxygen-induced retinopathy model could be inhibited...
January 2017: Molecular Pharmacology
https://www.readbyqxmd.com/read/27913442/comparison-of-anti-vegf-therapies-on-fibrovascular-pigment-epithelial-detachments-in-age-related-macular-degeneration
#20
Adrian Au, Vishal S Parikh, Rishi P Singh, Justis P Ehlers, Alex Yuan, Aleksandra V Rachitskaya, Jonathan E Sears, Sunil K Srivastava, Peter K Kaiser, Andrew P Schachat, Daniel F Martin, Yasha Modi
BACKGROUND: The aim is to compare the therapeutic effects of three antivascular endothelial growth factor (VEGF) drugs (bevacizumab, aflibercept and ranibizumab) on fibrovascular pigment epithelial detachments (fvPEDs) in age-related macular degeneration (AMD). METHODS: This was a retrospective, comparative, consecutive case series of 88 unique eyes with fvPEDs in neovascular AMD treated with anti-VEGF monotherapy for a minimum of 6 months. All eyes were treatment naive...
December 2, 2016: British Journal of Ophthalmology
keyword
keyword
36614
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"